Translational Consulting Research

Our Translational Consulting service bridges discovery‑stage research and regulated clinical development by upgrading exploratory assays, biomarker strategies, and analytical approaches into GLP‑ and GCP‑compliant standards. We support early‑stage biotech and pharma companies in transitioning research‑grade methods into robust, regulator‑ready frameworks.

 

Schedule a Call

Translational Consulting Research

We can support you with the scientific, technical, and regulatory transition from research assays to GLP/GCP‑ready methodologies, enabling confident progression into early‑phase clinical studies.

  • End‑to‑end biomarker strategy from identification to clinical application
  • Research assay translation into GLP/GCP‑compliant methods
  • Deep infectious disease and immunology expertise
  • Dedicated laboratory R&D team (8 PhDs)
  • Integrated clinical, analytical, and regulatory capabilities

Translational Assay Readiness

hVIVO_Lab_Services_ELISpot

 

 

 

 

• End‑to‑end biomarker strategy

• Scientific and regulatory consulting

• Assay development and GLP/GCP validation

• PK/PD and translational modelling

• Biomarker endpoint justification

• Phase‑specific analytical planning

• Cross‑functional laboratory and clinical expertise

Reason to Consider hVIVO

1

 Extensive experience bridging R&D and clinical development, and proven track record 

2

Integrated regulatory, laboratory and clinical capabilitiespabilites 

3

 Deep immunology and infectious disease expertise 

4

 Dedicated laboratory project leads (8 PhDs) 

For Biotechs

 Ideal for early‑stage companies needing translational expertise. 

Read more

For Pharmaceutical

Organisations advancing complex biomarkers or assays requiring robust qualification. 

Find out more

Development Stages Supported

Preclinical to First-In Human 

Read More
Featured Article

Custom Assay Design: Where Scientific Creativity Meets Regulatory Precision

Drug developers working in infectious diseases, oncology, autoimmune and advance modalities like cell and gene therapy, ADCs, RNA therapeutics (mRNA/RNAi) increasingly face a familiar challenge: the assays they need often don’t yet exist. Off‑the‑shelf solutions rarely answer the specific mechanistic questions regulators ask, and standard diagnostic platforms offer little room for adaptation. As therapeutics become more complex, the tools required to evaluate them must evolve just as quickly. That’s where custom assay design becomes essential. It’s not simply a technical exercise — it’s a form of scientific problem‑solving that blends creativity, regulatory awareness, and deep understanding of the mechanism of action. And it’s becoming one of the most important ways to de‑risk early‑phase development.

Elisa Masat
6 min read
View

FAQs

 Yes — we specialise in GLP/GCP translation and validation. 

Yes — we evaluate scientific relevance and regulatory acceptability.

Yes — we provide scientifically aligned justification text.

 Yes — we integrate PK/PD data to define safe starting doses. 

Contact Our Translational Consulting Team

Enquire now